🚀 VC round data is live in beta, check it out!
Haleon Overview
About Haleon
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Founded
2021
HQ
Employees
24.6K
Website
Sectors
Financials (LTM)
EV
$52B
Haleon Financials
Haleon reported last 12-month revenue of $15B and EBITDA of $4B.
In the same LTM period, Haleon generated $10B in gross profit, $4B in EBITDA, and $2B in net income.
Revenue (LTM)
Haleon P&L
In the most recent fiscal year, Haleon reported revenue of $15B and EBITDA of $4B.
Haleon expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15B | XXX | $15B | XXX | XXX | XXX |
| Gross Profit | $10B | XXX | $10B | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $4B | XXX | $4B | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | — | — | $10B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Haleon Stock Performance
Haleon has current market cap of $42B, and enterprise value of $52B.
Market Cap Evolution
Haleon's stock price is $4.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52B | $42B | 0.0% | XXX | XXX | XXX | $0.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHaleon Valuation Multiples
Haleon trades at 3.5x EV/Revenue multiple, and 13.4x EV/EBITDA.
EV / Revenue (LTM)
Haleon Financial Valuation Multiples
As of April 19, 2026, Haleon has market cap of $42B and EV of $52B.
Equity research analysts estimate Haleon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Haleon has a P/E ratio of 18.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $42B | XXX | $42B | XXX | XXX | XXX |
| EV (current) | $52B | XXX | $52B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 13.4x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBIT | 15.0x | XXX | 15.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | 5.5x | XXX | XXX | XXX |
| P/E | 18.3x | XXX | 18.8x | XXX | XXX | XXX |
| EV/FCF | 21.0x | XXX | 17.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Haleon Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Haleon Margins & Growth Rates
Haleon's revenue in the last 12 month grew by 4%.
Haleon's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Haleon's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Haleon's rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Haleon Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 40% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Haleon Public Comps
See public comps and valuation multiples for other Health & Beauty comps.
Valuation data powered by FactSet, Inc.
Haleon M&A Activity
Haleon acquired XXX companies to date.
Last acquisition by Haleon was on XXXXXXXX, XXXXX. Haleon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Haleon
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHaleon Investment Activity
Haleon invested in XXX companies to date.
Haleon made its latest investment on XXXXXXXX, XXXXX. Haleon invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Haleon
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Haleon
| When was Haleon founded? | Haleon was founded in 2021. |
| Where is Haleon headquartered? | Haleon is headquartered in United Kingdom. |
| How many employees does Haleon have? | As of today, Haleon has over 24K employees. |
| Who is the CEO of Haleon? | Haleon's CEO is Brian James McNamara. |
| Is Haleon publicly listed? | Yes, Haleon is a public company listed on London Stock Exchange. |
| What is the stock symbol of Haleon? | Haleon trades under HLN ticker. |
| When did Haleon go public? | Haleon went public in 2022. |
| Who are competitors of Haleon? | Haleon main competitors are Reckitt, Galderma, Bayer, Kenvue. |
| What is the current market cap of Haleon? | Haleon's current market cap is $42B. |
| What is the current revenue of Haleon? | Haleon's last 12 months revenue is $15B. |
| What is the current revenue growth of Haleon? | Haleon revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Haleon? | Current revenue multiple of Haleon is 3.5x. |
| Is Haleon profitable? | Yes, Haleon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Haleon? | Haleon's last 12 months EBITDA is $4B. |
| What is Haleon's EBITDA margin? | Haleon's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Haleon? | Current EBITDA multiple of Haleon is 13.4x. |
| What is the current FCF of Haleon? | Haleon's last 12 months FCF is $2B. |
| What is Haleon's FCF margin? | Haleon's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Haleon? | Current FCF multiple of Haleon is 21.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.